Amneal Pharmaceuticals (NASDAQ:AMRX) Now Covered by Analysts at UBS Group

UBS Group started coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX) in a report published on Friday, MarketBeat reports. The firm issued a buy rating on the stock.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $13.91 on Friday. The firm’s fifty day simple moving average is $13.23 and its 200-day simple moving average is $12.46. Amneal Pharmaceuticals has a 12 month low of $7.02 and a 12 month high of $15.42. The company has a market capitalization of $4.38 billion, a P/E ratio of 60.48 and a beta of 1.32.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AMRX. Kemnay Advisory Services Inc. purchased a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $26,000. Federated Hermes Inc. lifted its position in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares in the last quarter. Spire Wealth Management boosted its stake in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the last quarter. Transamerica Financial Advisors LLC boosted its stake in shares of Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares during the last quarter. Finally, Comerica Bank increased its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.